Pharmacogenomic Testing

Pharmacogenomic (PGx) testing identifies genetic variations that code for drug-metabolizing enzymes, transporters, and receptors. Changes in genetic function can impact how an individual will respond to specific medications.

Pharmacogenomic Testing

Pharmacogenomic (PGx) testing identifies genetic variations that code for drug-metabolizing enzymes, transporters, and receptors. Changes in genetic function can impact how an individual will respond to specific medications.

Benefits of PGx Testing

Test Panels

0%
99% of the population carries at least one mutation that affects drug metabolism.

PsychPainMarkers tests for variants in 3 genes associated with the safety and efficacy of 76 psychotropic and pain medications.

PGXMarkers tests 7 genes and predicts how a patient may respond to 125 medications. The PGXMarkers panel covers drugs used in the treatment of cardiology, gastroenterology, neurology, and psychiatric conditions, among others.

PGXMarkers Plus tests 20 genes associated with the safety and efficacy for 134 medications. PGXMarkers Plus provides clinical insight with applications to cardiology, psychiatry, gastroenterology, neurology, and other areas of clinical practice.

Genemarkers offers a single-gene test to predict the safety and efficacy of Clopidogrel.

Genemarkers’ Hyperhomocysteinemia single gene test analyzes variants in the MTHFR gene.

Testing Process

Billing Policy

Genemarkers is committed to providing patients with quality service. This includes ensuring a clear understanding of the billing process and access to a manageable payment arrangement. Most insurance plans, including Medicare and Medicaid, offer limited coverage of the test.

Genemarkers offers an affordable self-pay rate for each one of our panels for patients who are uninsured or those who have insurance and prefer not to bill their plan.

Genemarkers will submit the insurance claim on behalf of patients.

After the insurance claim has been processed to the fullest extent, Genemarkers will bill patients for any out-of-pocket expenses. This may be related to co-payments, co-insurance or deductibles.

Genemarkers has several options to help alleviate any financial burden due to out-of-pocket costs.

Medicare covers PGx testing for patients who meet medical necessity for the PGXMarkers and PainPsychMarkers Test Panels. Medicare covers tests that meet Medical Necessity at 100%. At this time, Medicare does not cover the PGXMarkers Plus Test Panel. Patients requesting the PGXMarkers Plus Panel are required to sign an Advance Beneficiary Notice of Non-Coverage (ABN) and may have out-of-pocket costs.

Genemarkers currently accepts Medicaid from several states. If the test is covered, there are no out-of-pocket costs.

Genemarkers has several financial support options to help alleviate any financial burden due to out-of-pocket costs, including:

prompt-pay discount

 zero interest payment plan

financial assistance plan for those who meet income-based guidelines

FAQs

Some insurance plans offer coverage of PGx testing. Coverage depends on the patient’s specific insurance carrier, their individual plan, and medical conditions. Genemarkers has established payment plans to help alleviate any financial hardship.

The test report is available 7-10 days after Genemarkers receives the sample, completed test requisition form, and necessary medical documentation.

PsychPainMarkers: 3 genes, 49 medications

PGXMarkers: 6 genes, 85 medications

PGXMarkers Plus: 18 genes, 135 medications

Single-gene Tests: Clopidogrel and Hyperhomocysteinemia

Request a testing kit today
or reach out to learn more!